Literature DB >> 20028654

Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production.

Stephen R Mattarollo1, Azad Rahimpour, Allison Choyce, Dale I Godfrey, Graham R Leggatt, Ian H Frazer.   

Abstract

NKT cells can promote or inhibit adaptive immune responses. Cutaneous immunity is tightly regulated by cooperation between innate and adaptive immune processes, but the role of NKT cells in regulating cutaneous immunity is largely unknown. In this study, we show, in a mouse model, that skin-infiltrating CD1d-restricted NKT cells in HPV16-E7 transgenic hyperplastic skin produce IFN-gamma, which can prevent rejection of HPV16-E7-expressing skin grafts. Suppression of graft rejection is associated with the accumulation of CD1d(hi)-expressing CD11c(+)F4/80(hi) myeloid cells in hyperplastic skin. Blockade of CD1d, removal of NKT cells, or local inhibition of IFN-gamma signaling is sufficient to restore immune-mediated graft rejection. Thus, inhibition of NKT cell recruitment or function may enable effective immunity against tumor and viral Ags expressed in epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028654     DOI: 10.4049/jimmunol.0902191

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia.

Authors:  Christina Gosmann; Stephen R Mattarollo; Jennifer A Bridge; Ian H Frazer; Antje Blumenthal
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

Review 2.  Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.

Authors:  Mary Speir; Ian F Hermans; Robert Weinkove
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

3.  NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins.

Authors:  Stephen R Mattarollo; Michelle Yong; Christina Gosmann; Allison Choyce; Dora Chan; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2011-07-08       Impact factor: 5.422

4.  A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Authors:  Salvatore Fiorenza; Tony J Kenna; Iain Comerford; Shaun McColl; Raymond J Steptoe; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2012-11-09       Impact factor: 5.422

5.  Donor-specific CD8+ Foxp3+ T cells protect skin allografts and facilitate induction of conventional CD4+ Foxp3+ regulatory T cells.

Authors:  N M Lerret; J L Houlihan; T Kheradmand; K L Pothoven; Z J Zhang; X Luo
Journal:  Am J Transplant       Date:  2012-06-08       Impact factor: 8.086

6.  In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.

Authors:  Shicheng Yang; Luca Gattinoni; Gattinoni Luca; Fang Liu; Yun Ji; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Immunol Immunother       Date:  2011-02-09       Impact factor: 6.968

7.  Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen.

Authors:  Stephen R Mattarollo; Michelle Yong; Lieven Tan; Ian H Frazer; Graham R Leggatt
Journal:  J Immunol       Date:  2010-04-21       Impact factor: 5.422

8.  iNKT cells suppress the CD8+ T cell response to a murine Burkitt's-like B cell lymphoma.

Authors:  Ryan L Bjordahl; Laurent Gapin; Philippa Marrack; Yosef Refaeli
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

9.  The immune response to papillomavirus during infection persistence and regression.

Authors:  Merilyn H Hibma
Journal:  Open Virol J       Date:  2012-12-28

10.  Expression of a single, viral oncoprotein in skin epithelium is sufficient to recruit lymphocytes.

Authors:  Allison Choyce; Michelle Yong; Sharmal Narayan; Stephen R Mattarollo; Amy Liem; Paul F Lambert; Ian H Frazer; Graham R Leggatt
Journal:  PLoS One       Date:  2013-02-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.